Literature DB >> 28314842

Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.

Rosalind P Candelaria1, Roland L Bassett2, William Fraser Symmans3, Maheshwari Ramineni3, Stacy L Moulder4, Henry M Kuerer5, Alastair M Thompson5, Wei Tse Yang6.   

Abstract

BACKGROUND: The primary objective was to determine whether mid-treatment ultrasound measurements of index breast tumors and index axillary nodes of different cancer subtypes associate with residual cancer burden (RCB).
METHODS: Patients with invasive breast cancer who underwent neoadjuvant chemotherapy and had pre-treatment and mid-treatment breast and axillary ultrasound were included in this single-institution, retrospective cohort study. Linear regression analysis assessed associations between RCB with (a) change in index breast tumor size, (b) change in index node size, and (c) absolute number of abnormal nodes at mid-treatment. Multivariate linear regression was used to calculate best-fit models for RCB.
RESULTS: One hundred fifty-nine patients (68 triple negative breast cancer [TNBC], 45 hormone receptor [HR]+/human epidermal growth factor receptor 2 [HER2]-, and 46 HR-/HER2+) were included. Median age at diagnosis was 50 years, range 30-76. Median tumor size was 3.4 cm, range 0.9-10.4. Pathological complete response/RCB-I rates were 36.8% (25/68) for TNBC patients, 24.4% (11/45) for HR+/HER2- patients, and 71.7% (33/46) for HR-/HER2+ patients. Linear regression analyses demonstrated associations between percent change in tumor ultrasound measurements at mid-treatment with RCB index score in TNBC and HR+/HER2- (p < .05) but not in HR-/HER2+ (p > .05) tumors and an association between axillary ultrasound assessment of number of abnormal nodes at mid-treatment with RCB index score across all subtypes (p < .05).
CONCLUSION: Performance characteristics of breast ultrasound associated with RCB vary by cancer subtype, whereas the performance characteristics of axillary ultrasound associated with RCB are consistent across cancer subtype. Breast and axillary ultrasound may be valuable in monitoring response to neoadjuvant therapy. The Oncologist 2017;22:394-401 IMPLICATIONS FOR PRACTICE: The differential performance characteristics of breast ultrasound by molecular subtype and the consistent performance characteristics of axillary ultrasound across molecular subtypes can have clinical utility in monitoring response to neoadjuvant therapy. © AlphaMed Press 2017.

Entities:  

Keywords:  Breast cancer; Neoadjuvant therapy; Ultrasound

Mesh：

Substances：

Year:  2017        PMID： 28314842      PMCID： PMC5388386          DOI： 10.1634/theoncologist.2016-0307

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  36 in total

1.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

Review 2.  Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients.

Authors:  Xiangnan Kong; Meena S Moran; Ning Zhang; Bruce Haffty; Qifeng Yang
Journal:  Eur J Cancer       Date:  2011-07-05       Impact factor: 9.162

3.  Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.

Authors:  Claudette E Loo; Marieke E Straver; Sjoerd Rodenhuis; Sara H Muller; Jelle Wesseling; Marie-Jeanne T F D Vrancken Peeters; Kenneth G A Gilhuijs
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.

Authors:  Aida Kuzucan; Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Peter T Fwu; Hon J Yu; David J B Hsiang; Karen T Lane; John A Butler; Stephen A Feig; Min-Ying Su
Journal:  Clin Breast Cancer       Date:  2012-04       Impact factor: 3.225

5.  MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes.

Authors:  Hiroshi Nakahara; Yukiko Yasuda; Eiichiro Machida; Yorio Maeda; Hidemi Furusawa; Kansei Komaki; Mayumi Funagayama; Mayumi Nakahara; Shozo Tamura; Futoshi Akiyama
Journal:  Breast Cancer       Date:  2010-11-18       Impact factor: 4.239

6.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

7.  Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.

Authors:  Elena Provenzano; Veerle Bossuyt; Giuseppe Viale; David Cameron; Sunil Badve; Carsten Denkert; Gaëtan MacGrogan; Frédérique Penault-Llorca; Judy Boughey; Giuseppe Curigliano; J Michael Dixon; Laura Esserman; Gerd Fastner; Thorsten Kuehn; Florentia Peintinger; Gunter von Minckwitz; Julia White; Wei Yang; W Fraser Symmans
Journal:  Mod Pathol       Date:  2015-07-24       Impact factor: 7.842

8.  Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment.

Authors:  H-G Moon; W Han; J W Lee; E Ko; E-K Kim; J-H Yu; S Y Kang; W K Moon; N Cho; I-A Park; D-Y Oh; S-W Han; S-A Im; D-Y Noh
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

9.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

10.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534
View more
  7 in total

1.  Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.

Authors:  Na Lae Eun; Eun Ju Son; Hye Mi Gweon; Jeong-Ah Kim; Ji Hyun Youk
Journal:  Eur Radiol       Date:  2019-12-04       Impact factor: 5.315

2.  Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer.

Authors:  Rosalind P Candelaria; Beatriz E Adrada; Deanna L Lane; Gaiane M Rauch; Stacy L Moulder; Alastair M Thompson; Roland L Bassett; Elsa M Arribas; Huong T Le-Petross; Jessica W T Leung; David A Spak; Elizabeth E Ravenberg; Jason B White; Vicente Valero; Wei T Yang
Journal:  Ultrasound Med Biol       Date:  2022-03-14       Impact factor: 2.998

3.  Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy.

Authors:  Jürgen Geisler; Jonn Terje Geitung; Joana Reis; Joao Boavida; Hang T Tran; Marianne Lyngra; Laurens Cornelus Reitsma; Hossein Schandiz; Woldegabriel A Melles; Kjell-Inge Gjesdal
Journal:  BMC Cancer       Date:  2022-06-25       Impact factor: 4.638

4.  Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?

Authors:  Geok Hoon Lim; Mihir Gudi; Sze Yiun Teo; Ruey Pyng Ng; Zhiyan Yan; Yien Sien Lee; John C Allen; Lester Chee Hao Leong
Journal:  Oncologist       Date:  2020-07-07

5.  A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity.

Authors:  J K Litton; M Scoggins; D L Ramirez; R K Murthy; G J Whitman; K R Hess; B E Adrada; S L Moulder; C H Barcenas; V Valero; J Schwartz Gomez; E A Mittendorf; A Thompson; T Helgason; G B Mills; H Piwnica-Worms; B K Arun
Journal:  NPJ Breast Cancer       Date:  2017-12-06

6.  Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.

Authors:  Anna Weiss; Sami I Bashour; Kenneth Hess; Alastair M Thompson; Nuhad K Ibrahim
Journal:  Breast Cancer Res       Date:  2018-04-16       Impact factor: 6.466

Review 7.  Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.

Authors:  Ella F Jones; Deep K Hathi; Rita Freimanis; Rita A Mukhtar; A Jo Chien; Laura J Esserman; Laura J Van't Veer; Bonnie N Joe; Nola M Hylton
Journal:  Cancers (Basel)       Date:  2020-06-09       Impact factor: 6.575
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.